# EDGAR Filing Document

**Accession Number:** 0000897448
**File Stem:** 0001193125-23-008947
**Filing Date:** 2023-1
**Character Count:** 80299
**Document Hash:** 811de54eff0a88d99cd9e8106a53643d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-008947.hdr.sgml**: 20230117

**ACCESSION NUMBER**: 0001193125-23-008947

**CONFORMED SUBMISSION TYPE**: PREC14A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20230117

**DATE AS OF CHANGE**: 20230117

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AMARIN CORP PLC\UK
- **CENTRAL INDEX KEY:** 0000897448
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** PREC14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-21392
- **FILM NUMBER:** 23530306

**BUSINESS ADDRESS:**
- **STREET 1:** SPACES SOUTH DOCKLANDS, BLOCK C
- **STREET 2:** 77 SIR JOHN ROGERSON'S QUAY
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 VK60
- **BUSINESS PHONE:** 353 1 6699 020

**MAIL ADDRESS:**
- **STREET 1:** SPACES SOUTH DOCKLANDS, BLOCK C
- **STREET 2:** 77 SIR JOHN ROGERSON'S QUAY
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 VK60

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMARIN PHARMACEUTICALS PLC
- **DATE OF NAME CHANGE:** 20000201

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ETHICAL HOLDINGS PLC
- **DATE OF NAME CHANGE:** 19930322
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AMARIN CORP PLC\UK
- **CENTRAL INDEX KEY:** 0000897448
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** PREC14A

**BUSINESS ADDRESS:**
- **STREET 1:** SPACES SOUTH DOCKLANDS, BLOCK C
- **STREET 2:** 77 SIR JOHN ROGERSON'S QUAY
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 VK60
- **BUSINESS PHONE:** 353 1 6699 020

**MAIL ADDRESS:**
- **STREET 1:** SPACES SOUTH DOCKLANDS, BLOCK C
- **STREET 2:** 77 SIR JOHN ROGERSON'S QUAY
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 VK60

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMARIN PHARMACEUTICALS PLC
- **DATE OF NAME CHANGE:** 20000201

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ETHICAL HOLDINGS PLC
- **DATE OF NAME CHANGE:** 19930322

##### [**Table of Contents**](#toc)

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

------

**SCHEDULE 14A** 

**Proxy Statement Pursuant to Section 14(a) of the** 

**Securities Exchange Act of 1934** 

**(Amendment No.)** 

------

Filed by the Registrant ☒

Filed by a party other than the Registrant ☐

Check the appropriate box:

☒ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))** 

☐ Definitive Proxy Statement

☐ Definitive Additional Materials

☐ Soliciting Material under § 240.14a-12

**AMARIN CORPORATION PLC** 

**(Name of Registrant as Specified In Its Charter)** 

**N/A** 

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)** 

Payment of Filing Fee (Check all boxes that apply):

☒ No fee required

☐ Fee paid previously with preliminary materials

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

------

##### [**Table of Contents**](#toc)
![LOGO](g424531g76b14.jpg)

**77 Sir John Rogerson's Quay, Block C** 

**Grand Canal Docklands, Dublin 2, Ireland** 

**(Registered in England & Wales under Company No. 2353920)** 

**NOTICE IS HEREBY GIVEN** that a general meeting of the shareholders (the "***General Meeting***") of Amarin Corporation plc, a public limited company registered in England and Wales (the "***Company***" or "***we***"), will be held at [●], on [●], 2023 at [●] [a.m./p.m.] local time. The Board of Directors of the Company (the "***Board***") is calling the General Meeting following a requisition notice received from (i) Sarissa Capital Catapult Fund LLC, (ii) Sarissa Capital Hawkeye Fund LP, (iii) ISP Fund LP, (iv) Sarissa Capital Offshore Master Fund LP, (v) Sarissa Capital Master Fund II LP and (vi) Sarissa Capital Athena Fund Ltd (collectively, the "***Sarissa Holders***"), which are funds affiliated with Sarissa Capital Management LP ("***Sarissa Capital***" and, together with the Sarissa Holders and other funds and investment vehicles affiliated with Sarissa Capital, "***Sarissa***") on January 10, 2023 requiring the Company to convene the General Meeting (the "***Requisition Notice***") pursuant to section 303 of the Companies Act 2006 (the "***Companies Act***") for the purposes of considering and voting on the below resolutions, all of which are proposed as ordinary resolutions. At the date of delivery of the Requisition Notice, the Sarissa Holders were registered holders of an aggregate amount of 20,300,000 ordinary shares, nominal value 50 pence per share of the Company, which constituted approximately 5.02 per cent of the Company's issued share capital as carries the right of voting at general meetings of the Company. The accompanying proxy statement is dated [●], 2023, and together with the enclosed form of proxy card, is first being sent to shareholders on or about [●], 2023.

The purpose of the general meeting will be to consider the following resolutions:

1. That Per Wold-Olsen be removed from office as a director of the Company with immediate effect;

2. That in the event any director is appointed after the Company's receipt of the general meeting requisition
notice dated January 10, 2023, and prior to the general meeting, each such director be removed from office as a director of the Company with immediate effect; and

3. That each of Patrice Bonfiglio, Paul Cohen, Mark DiPaolo, Keith L. Horn, Odysseas Kostas, Louis Sterling III
and Diane E. Sullivan, having consented to act, be appointed as an additional director of the Company with immediate effect.

**Our Board believes that the resolutions will not promote the success of, and are not in the best interests of, the Company and its shareholders as a whole. The Board therefore unanimously recommends you vote the WHITE proxy card "AGAINST" all of the resolutions to be proposed at the General Meeting.** 

**You may receive solicitation materials from Sarissa, including a proxy statement and proxy card. We are not responsible for the accuracy of any information provided by or related to Sarissa or their nominees contained in solicitation materials filed or disseminated by them or on their behalf of or any other statements they or their representatives may make.** 

**AFTER CAREFUL CONSIDERATION, OUR BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE "AGAINST" ALL OF THE RESOLUTIONS TO BE PROPOSED AT THE GENERAL MEETING USING THE ENCLOSED WHITE PROXY CARD OR BY FOLLOWING THE INSTRUCTIONS TO SUBMIT A PROXY FOR YOUR SHARES.** 

**The Nominating and Corporate Governance Committee of the Board has conducted an evaluation of each of the director nominees proposed by Sarissa. On the basis of this review, our Board urges you <u>not</u> to sign or return any proxy card sent to you by Sarissa.** 

The Company does not expect that other items of business will be considered at the General Meeting.

------

##### [**Table of Contents**](#toc)
Only shareholders who held shares at the close of business on the record date, [●], 2023, may vote at the General Meeting, including any adjournment or postponement thereof. The accompanying Proxy Statement more fully describes the details of the business to be conducted at the General Meeting.

The Company's principal executive offices are located at 77 Sir John Rogerson's Quay, Block C, Grand Canal Docklands, Dublin 2, Ireland. The registered office of the Company is One New Change, London EC4M 9AF, England.

As a public limited company organized under the laws of England and Wales and pursuant to the Company's Articles of Association, the presence, in person or by proxy, of at least two shareholders entitled to vote at the General Meeting constitutes a quorum for the transaction of business at the General Meeting. Consistent with the marketplace rules of the Nasdaq Stock Market, we will seek to ensure that the two shareholders present at the meeting in person or by proxy represent at least one-third of our outstanding shares of voting stock.

**YOUR VOTE IS IMPORTANT. A SHAREHOLDER OR ADS HOLDER MUST ACTIVELY VOTE TO HAVE AN IMPACT ON THE OUTCOME, POSITIVE OR NEGATIVE. WE STRONGLY ENCOURAGE SHAREHOLDERS AND ADS HOLDERS TO VOTE AND VOTE AGAINST ALL RESOLUTIONS IN ADVANCE OF THE GENERAL MEETING BY COMPLETING, DATING, SIGNING AND RETURNING A WHITE PROXY OR VOTING INSTRUCTION FORM AS PROMPTLY AS POSSIBLE IN ORDER TO ENSURE YOUR REPRESENTATION AT THE GENERAL MEETING. NOT VOTING OR ABSTAINING FROM VOTING WILL NOT HELP DEFEAT THESE HARMFUL RESOLUTIONS. IF YOU HAVE ANY QUESTIONS OR NEED ASSISTANCE VOTING YOUR SHARES, PLEASE CONTACT THE COMPANY'S PROXY SOLICITORS, MORROW SODALI LLC AND OKAPI PARTNERS LLC, AT:** 

---

| | |
|:---|:---|
| Morrow Sodali LLC<br> 509 Madison Avenue, 12th Floor<br> New York, NY 10022<br> Toll-free: 1 (800) 662-5200<br> Collect: 1 (203) 658-9400<br> Email: AMRN@info.morrowsodali.com | ![LOGO](g424531g31y03.jpg) <br>1212 Avenue of the Americas, 17th Floor<br> New York, NY 10036<br> Telephone for Banks, Brokers, and International<br> Shareholders: +1 212-297-0720<br> Shareholders may call toll-free (from the U.S. and<br> Canada): 844-343-2625<br> Email: info@okapipartners.com |

---

---

| |
|:---|
| Sincerely, |
| Karim Mikhail |
| *President and Chief Executive Officer* |

---

------

##### [**Table of Contents**](#toc)
**AMARIN CORPORATION PLC** 

**PROXY STATEMENT FOR** 

**GENERAL MEETING OF SHAREHOLDERS** 

**TABLE OF CONTENTS** 

---

| | |
|:---|:---|
|  [GENERAL INFORMATION](#toc424531_1) | 1 |
|  [FORWARD-LOOKING STATEMENTS](#toc424531_2) | 4 |
|  [BACKGROUND OF THE SOLICIATION](#toc424531_3) | 5 |
| [PROPOSAL NO. 1 THAT PER WOLD-OLSEN BE REMOVED FROM OFFICE AS A DIRECTOR OF THE COMPANY WITH IMMEDIATE EFFECT](#toc424531_4) | 7 |
| [PROPOSAL NO. 2 THAT IN THE EVENT ANY DIRECTOR IS APPOINTED AFTER THE COMPANY'S RECEIPT OF THE REQUISITION NOTICE, AND PRIOR TO THE GENERAL MEETING, EACH SUCH DIRECTOR BE REMOVED FROM OFFICE AS A DIRECTOR OF THE COMPANY WITH IMMEDIATE EFFECT](#toc424531_5) | 8 |
| [PROPOSAL NO. 3 THAT EACH OF PATRICE BONFIGLIO, PAUL COHEN, MARK DIPAOLO, KEITH L. HORN, ODYSSEAS KOSTAS, LOUIS STERLING III AND DIANE E. SULLIVAN, HAVING CONSENTED TO ACT, BE APPOINTED AS AN ADDITIONAL DIRECTOR OF THE COMPANY WITH IMMEDIATE EFFECT.](#toc424531_6) | 9 |
|  [ADDITIONAL BUSINESS](#toc424531_7) | 11 |
|  [SOLICITATION OF PROXIES](#toc424531_8) | 11 |
|  [SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT](#toc424531_9) | 12 |
|  [PROXY FORM](#toc424531_10) | 14 |
|  [SUPPLEMENTAL INFORMATION REGARDING PARTICIPANTS](#toc424531_11) | 16 |

---

------

##### [**Table of Contents**](#toc)
**PRELIMINARY PROXY STATEMENT – SUBJECT TO COMPLETION** 

**GENERAL MEETING OF SHAREHOLDERS** 

**TO BE HELD ON** [●]**, 2023** 

**GENERAL INFORMATION** 

This Proxy Statement is furnished in connection with the solicitation of proxies by the Board of Directors (the "***Board***") of Amarin Corporation plc, a public limited company registered in England & Wales ("***Amarin***", the "***Company***", "***we***" or "***us***") for use at the general meeting of shareholders (the "***General Meeting***"), which is being convened following the Board's receipt of a notice from a requisition notice received from (i) Sarissa Capital Catapult Fund LLC, (ii) Sarissa Capital Hawkeye Fund LP, (iii) ISP Fund LP, (iv) Sarissa Capital Offshore Master Fund LP, (v) Sarissa Capital Master Fund II LP and (vi) Sarissa Capital Athena Fund Ltd (collectively, the "***Sarissa Holders***"), which are funds affiliated with Sarissa Capital Management LP ("***Sarissa Capital***" and, together with the Sarissa Holders and other funds and investment vehicles affiliated with Sarissa Capital, "***Sarissa***") on January 10, 2023 requiring the Company to convene the General Meeting (the "***Requisition Notice***") pursuant to section 303 of the Companies Act 2006 (the "***Companies Act***") for the purposes of considering and voting on the below resolutions, all of which are proposed as ordinary resolutions. The Requisition Notice was delivered in accordance with section 303 of the United Kingdom Companies Act 2006 (the "***Companies Act***"). The General Meeting will be held at [●] on [●], 2023 at [●] [a.m./p.m.] local time for the purpose of considering and, if thought fit, passing the resolutions specified in the Notice of General Meeting, all of which are proposed as ordinary resolutions.

Please vote on the ordinary resolutions specified in the Notice of General Meeting by appointing a proxy. A form of **WHITE** proxy for use by registered holders of ordinary shares, nominal value 50 pence per share of the Company ("***Ordinary Shares***") at the General Meeting is enclosed. Our Board believes that the resolutions will not promote the success of, and are not in the best interests of, the Company and its shareholders as a whole. The Board therefore unanimously recommends that you vote the **WHITE** proxy card "AGAINST" all of the resolutions to be proposed at the General Meeting. The Nominating and Corporate Governance Committee of the Board (the "***NCG Committee***") has conducted an evaluation of each of the nominees proposed by Sarissa (the "***Sarissa Nominees***"). On the basis of this review, our Board urges you not to sign or return any proxy card sent to you by Sarissa.

For a proxy to be effective, it must be properly executed and dated and lodged (together with a duly signed and dated power of attorney or other authority (if any) under which it is executed (or a notarially certified copy of such power of attorney or other authority)) at the offices of the Company's registrars, Equiniti Limited of Aspect House, Spencer Road, Lancing, West Sussex, BN99 6DA, England (the "***Registrars***") so as to be received by [●] [a.m./p.m.] local time on [●], 2023 (the "***Ordinary Share Instruction Date***"). Each proxy properly tendered will, unless otherwise directed by the shareholder, be voted "AGAINST" all of the resolutions to be proposed at the General Meeting, and at the discretion of the proxy holder(s) with regard to all other matters that may properly come before the meeting.

Please note Sarissa has proposed individuals for election as directors at the General Meeting in an attempt to replace one of our current Board members and appoint seven additional directors to our Board. You may receive solicitation materials from Sarissa, including a proxy statement and proxy card. Please refer to Sarissa's proxy statement for information related to their director nominees. You may access Sarissa's proxy statement, and any other relevant documents, without cost on the Securities and Exchange Commission's ("***SEC***") website. We are not responsible for the accuracy of any information provided by or related to Sarissa or its nominees contained in solicitation materials filed or disseminated by them or on their behalf of or any other statements they or its representatives may make.

------

##### [**Table of Contents**](#toc)
**Shares Outstanding and Voting Rights** 

Amarin is registered in England & Wales and is therefore subject to the Companies Act, which, together with the Articles of Association of the Company (the "***Articles***"), governs the processes for shareholder voting at general meetings. There are a number of differences between English and U.S. law in relation to voting. At the General Meeting, a resolution put to the vote of the meeting shall be decided on a show of hands unless a poll is demanded (either before or immediately after the result of a show of hands on that resolution is declared or on the withdrawal of any other demand for a poll) by (a) the Chairman of the meeting, (b) at least two shareholders of the Company entitled to vote at the meeting, (c) a shareholder or shareholders of the Company representing not less than one-tenth of the total voting rights of all shareholders having the right to vote at the meeting (excluding any voting rights attached to shares in the Company that are held as treasury shares) or (d) a shareholder or shareholders of the Company holding shares conferring a right to vote at the meeting being shares on which an aggregate sum has been paid up equal to not less than one-tenth of the total sum paid up on all shares conferring that right (excluding any shares in the Company conferring a right to vote at the meeting that are held as treasury shares).

Only holders of record of our Ordinary Shares at the close of business on [●], 2023 (the "***Record Date***"), are entitled to notice of, and to attend and to vote at, the General Meeting. On the Record Date, approximately [●] Ordinary Shares were issued and [●] were outstanding and entitled to vote at the General Meeting, of which approximately [●] were held in the name of the Depositary (as defined below), which issues Company-sponsored American Depositary Shares ("***ADSs***" and, together with Ordinary Shares, "***Shares***") which, in turn, each represent one Ordinary Share. With respect to all matters to be voted on at the General Meeting, each shareholder present has only one vote unless demand is made for a vote on a poll (in which case each shareholder gets one vote per Ordinary Share held). The presence, in person or by proxy, of at least two shareholders who hold Ordinary Shares as of the Record Date will constitute a quorum for the transaction of business at the General Meeting. Consistent with the marketplace rules of the Nasdaq Stock Market, we will seek to ensure that the two shareholders present at the meeting in person or by proxy represent at least one-third of our outstanding shares of voting stock.

Persons who hold Ordinary Shares directly on the Record Date ("***record holders***") must return a proxy card in order to vote on the proposals.

Persons who hold ADSs through a bank, broker or nominee on the Record Date will receive documentation and instructions for voting such ADSs at the General Meeting, including the ADS voting instruction form, through such organization. The organization holding your account is considered the ADS record holder. Please reach out to that organization to provide your voting instructions.

ADS holders are not entitled to vote directly at the General Meeting, but an Amended and Restated Deposit Agreement dated as of November 4, 2011 (the "***Deposit Agreement***"), exists among the Company, Citibank, N.A. (the "***Depositary***") and all holders and beneficial owners of ADSs issued thereunder pursuant to which registered holders of ADSs as of the Record Date are entitled to instruct the Depositary as to the exercise of voting rights pertaining to the Ordinary Shares so represented. The Depositary has agreed that it will endeavor, insofar as practicable, to vote (in person (if permitted) or by delivery to the Company of a proxy) the Ordinary Shares registered in the name of the Depositary, in accordance with the instructions of the ADS holders. In the event that the Depositary timely receives voting instructions from an ADS holder which fail to specify the manner in which the Depositary is to vote the Ordinary Shares represented by such holder's ADSs, the Depositary will deem such ADS holder (unless otherwise specified in the notice distributed to ADS Holders) to have instructed the Depositary to vote in favor of the items set forth in such voting instructions. Instructions from ADS holders must be sent to the Depositary so that the instructions are received by no later than [●] [a.m./p.m.] New York time on [●], 2023 (the "***ADS Instruction Date***"). **ADS holders are therefore strongly encouraged to submit their voting instructions as soon as possible. Ordinary Shares represented by the ADSs for which ADS holders have not timely submitted valid voting instructions shall not be voted.**

------

##### [**Table of Contents**](#toc)
Persons who own Ordinary Shares indirectly on the Record Date through a brokerage firm, bank or other financial institution, must return a voting instruction form to such brokerage firm, bank or other financial institution to have their Ordinary Shares voted on their behalf. We encourage you to provide voting instructions to your brokerage firm, bank or other financial institution by giving your proxy to them as promptly as possible to ensure that your Ordinary Shares will be voted at the General Meeting according to your instructions. You should receive a WHITE voting instruction form from your brokerage firm, bank or other financial institution about how to submit your voting instructions to them at the time you receive this Proxy Statement.

The Company has retained the Registrars to hold and maintain its register of members. The Registrars will be engaged by the Company to send proxy forms to all registered members appearing on that register and to take delivery of completed proxy forms posted to it in accordance with the details above.

Each of the proposals will be approved if (i) on a show of hands, a majority of shareholders present in person or by proxy and voting on such proposal vote in favor of removing such director or (ii) on a poll, a majority of the shares present at the meeting in person or by proxy and voting on the proposal are voted in favor of removing such director. As a result, abstentions and broker non-votes will have no effect on the vote outcome. Abstentions and broker non-votes will be counted for the purpose of determining the presence of absence of a quorum, but will not be counted for the purpose of determining the number of votes cast on a given proposal.

Sarissa is reported to beneficially own approximately 25,210,000 Shares as of January 10, 2023. Sarissa has proposed individuals for election as directors at the General Meeting in an attempt to replace one of our current Board members and appoint seven additional directors to our Board. **Our Board believes that the resolutions will not promote the success of, and are not in the best interests of, the Company and its shareholders as a whole. The Board therefore unanimously recommends that you vote the WHITE proxy card "AGAINST" all of the resolutions to be proposed at the General Meeting.** The NCG Committee has conducted an evaluation of each of the Sarissa Nominees. On the basis of this review, our Board urges you not to sign or return any proxy card sent to you by Sarissa.

To ensure your vote is counted on the proposed resolutions, shareholders are strongly encouraged to appoint the Chairman of the General Meeting as your proxy through the process described in this Proxy Statement. By voting in advance of the meeting, this ensures that your shares will be voted and reduces the likelihood that the Company will be forced to incur additional expenses soliciting proxies for the General Meeting. Any record holder of our Ordinary Shares may attend the General Meeting in person and may revoke the enclosed form of proxy at any time by:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• executing and delivering to the corporate secretary a later-dated proxy; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• voting in person at the General Meeting.

Beneficial owners of our Ordinary Shares and ADSs representing our Ordinary Shares who wish to change or revoke their voting instructions should contact their brokerage firm, bank or other financial institution, as applicable, for information on how to do so. Generally, however, beneficial owners of our Ordinary Shares who wish to change or revoke their voting instructions may do so up until the Ordinary Shares Instruction Date or the ADS Instruction Date, as the case may be. To ensure your vote is counted on the proposed resolutions, shareholders are strongly encouraged to appoint the Chairman of the General Meeting as your proxy through the process described in this Proxy Statement. Beneficial owners of our Ordinary Shares who wish to attend the General Meeting and vote in person should contact their brokerage firm, bank or other financial institution holding Ordinary Shares of the Company on their behalf in order to obtain a "legal proxy" which will allow them to both attend the meeting and vote in person. Without a legal proxy, beneficial owners cannot vote in person at the General Meeting because their brokerage firm, bank or other financial institution may have already voted or returned a broker non-vote on their behalf. Record holders of ADSs who wish to attend the General Meeting and vote in person should contact the Depositary (and beneficial owners wishing to do the same should contact their brokerage firm, bank or other financial institution holding their ADSs) to cause their ADSs to be cancelled and

------

##### [**Table of Contents**](#toc)
the underlying shares to be withdrawn in accordance with the terms and conditions of the Deposit Agreement so as to be recognized by us as a record holder of our Ordinary Shares.

**If you have any questions or need assistance voting your shares, please contact the Company's proxy solicitors, Morrow Sodali LLC and Okapi Partners LLC, at:** 

---

| | |
|:---|:---|
| <br> Morrow Sodali LLC<br> 509 Madison Avenue, 12th Floor<br> New York, NY 10022<br> Toll-free: 1 (800) 662-5200<br> Collect: 1 (203) 658-9400<br> Email: AMRN@info.morrowsodali.com | ![LOGO](g424531g31y03.jpg) <br>1212 Avenue of the Americas, 17th Floor<br> New York, NY 10036<br> Telephone for Banks, Brokers, and International<br> Shareholders: +1 212-297-0720<br> Shareholders may call toll-free (from the U.S. and<br> Canada): 844-343-2625<br> Email: info@okapipartners.com |

---

**FORWARD-LOOKING STATEMENTS** 

This Proxy Statement contains certain "forward-looking statements" relating to future events. Such statements are only predictions and involve risks and uncertainties, resulting in the possibility that the actual events or performance will differ materially from such predictions. For a nonexclusive list of major factors which could cause the actual results to differ materially from the predicted results in these forward-looking statements, please refer to the "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021, and in our subsequently filed quarterly reports on Form 10-Q and our current reports on Form 8-K. Those factors are not ranked in any particular order.

------

##### [**Table of Contents**](#toc)
**BACKGROUND OF THE SOLICIATION** 

On November 15, 2021, Sarissa filed a Form 13F disclosing a 3.4% position in Amarin.

On January 24, 2022, Sarissa filed a Schedule 13D disclosing an increase in its position in Amarin to 6.06% and its intention to engage in discussions with the Company regarding "its investment … and ways to maximize the value of [Amarin's] assets."

On March 2, 2022, representatives of the Company attended a virtual meeting with Sarissa. During this meeting, the Company's representatives discussed, among other things, Amarin's pricing and geographical opportunities in Europe and the Middle East. During the meeting, the Sarissa representatives indicated Sarissa's desire to propose a member to the Board but did not name any specific potential nominees.

On May 19, 2022, Karim Mikhail, the Company's President and Chief Executive Officer as well as a director, sent an email to Sarissa representatives indicating that the Board has discussed Sarissa's request to propose a Board member and requesting the name and background of any potential nominees as well as Sarissa's availability for in-person meetings in early to mid-June.

Throughout May and June of 2022, the Company and Sarissa had subsequent correspondence regarding Sarissa providing potential nominees to the Board. During this correspondence Sarissa declined to provide the names of potential nominees to the Board despite the Company's repeated requests that they do so.

On June 3, 2022, Sarissa filed an amendment to its Schedule 13D. The amendment disclosed no change in ownership but made reference to "investor concerns about the ability of leadership as currently constituted to navigate [the Company] during this critical time." Sarissa also stated that its principals intended to seek representation on the Board.

On June 15, 2022, Sarissa published a press release disclosing that Sarissa had been in discussions with the Company regarding its proposal to add directors to the Board and that Sarissa intended to vote "abstain" on all matters at the Annual Meeting. Also on June 15, 2022, Sarissa provided the Company with completed director and officer questionnaires for five proposed nominees: Odysseas Kostas, Mark DiPaolo, Patrice Bonfiglio, Shenstone Huang and Eric Trac. At the time, all were employees of Sarissa. Sarissa demanded that at least three of these individuals be appointed in a matter of days after the names were disclosed, asking the Board to abandon corporate governance best practices and circumvent the NCG Committee's established process for evaluating director nominations.

On June 27, 2022, the Company held its Annual General Meeting. All matters set forth in the Company's proxy statement for the Annual General Meeting were approved by the Company's shareholders.

During July 2022, the Company engaged in further correspondence with Sarissa regarding the nominees in light of its ongoing refreshment process. The Company and Sarissa ultimately agreed to set up interviews with Mr. Kostas, Mr. DiPaolo and Ms. Bonfiglio and the NCG Committee. The Company made it clear that the Sarissa candidates would be evaluated against the Company's preexisting established criteria and requested the availability of the Sarissa Candidates for the interviews.

------

##### [**Table of Contents**](#toc)
On August 3, 2022, Sarissa requested a call with the Company to discuss the Company's earnings from the second quarter. An approximately thirty-minute call was held later on the same day. The Sarissa team then requested an additional thirty-minute call to discuss the remainder of their questions regarding the Company's earnings from the second quarter. Another follow-up call was held on August 9, 2022

During August 2022, members of the NCG Committee interviewed each of the Sarissa Candidates.

On August 30, 2022, the NCG Committee recommended to the Board that each of the three Sarissa Candidates be interviewed by the remaining five members of the Board.

On October 11, 2022, Sarissa issued a press release indicating that it had commenced the process to requisition a general meeting of the Company to remove and replace certain directors. On the same day, Sarissa filed a Schedule 13D amendment reporting the commencement of the shareholder-requisitioned general meeting process and a 5.95% ownership position in Amarin.

On October 11, 2022, the Company issued a press release indicating that the Company has engaged with Sarissa in good faith and evaluated all potential board candidates with a defined and tailored list of necessary skillsets and that the Board's consideration of these candidates, including the Sarissa Candidates, was in final stages. The press release also noted that the Company's ongoing Board refreshment process, with the assistance of a renowned search firm, had already resulted in the appointment of three independent directors in the past year which added extensive and applicable experience and expertise to the Board.

On October 20, 2022, the Company appointed Adam Berger and Geraldine Murphy to the Board to serve until the Company's 2023 annual general meeting of shareholders. The Company also announced that directors Lars Ekman and Patrick O'Sullivan would retire from the Board, effective as of December 31, 2022.

Also on October 20, 2022, the chairman of the Board, Per Wold-Olsen, when unable to connect with Mr. DiPaolo by phone, emailed Mr. DiPaolo to inform him that the Board had decided not to proceed with his candidacy as a director of the Company.

On October 27, 2022, Mr. Wold-Olsen met with Mr. DiPaolo.

On January 5, 2023, the Company filed an amended Form 8-K in which it announced that, in connection with the retirement of Lars Ekman and Patrick J. O'Sullivan, on January 5, 2023, the Board appointed Adam Berger and Geraldine Murphy to the NCG Committee, designating Mr. Berger as Chair, effective immediately.

On January 10, 2023, the Company filed a Form 8-K announcing that, on January 9, 2023, the Board appointed Murray Stewart, DM, FRCP to the Board in connection with its ongoing refreshment process.

On January 10, 2023, Sarissa delivered the Requisition Notice to the Company, which indicated three separate proposals to be put forth as ordinary resolutions. The proposals provided that (i) Per Wold-Olsen be removed from office as a director of the Company, (ii) in the event any director is appointed after the Company's receipt of the general meeting requisition notice dated January 10, 2023, each such director be removed from office as a director of the Company with immediate effect, and (iii) Mr. Kostas, Mr. DiPaolo, Ms. Bonfiglio, Paul Cohen, Keith L. Horn, Louis Sterling III and Diane E. Sullivan each be appointed as a director of the Company with immediate effect. Simultaneous with the delivery of the Requisition Notice to the Company, Sarissa also delivered to the Company a request for a copy for a register of the Company's members (the "***Register Request***").

On January 11, 2023, Sarissa filed an amended Schedule 13D in which it disclosed an ownership position of approximately 6.24% in Amarin as well as its delivery of the Requisition Notice to the Company.

On January 16, 2023, on behalf of Amarin, representatives of Ropes & Gray LLP, as counsel to Amarin, delivered a response letter to Sarissa to clarify certain points with respect to the Requisition Notice and the Register Request.

------

##### [**Table of Contents**](#toc)
**PROPOSAL NO. 1** 

**THAT PER WOLD-OLSEN BE REMOVED FROM OFFICE AS A DIRECTOR OF THE COMPANY WITH IMMEDIATE EFFECT** 

Sarissa has proposed that Per Wold-Olsen be removed from office as a director of the Company with immediate effect.

Mr. Wold-Olsen joined Amarin as a non-executive director in January 2022. On May 16, 2022, the Board appointed Mr. Wold-Olsen as chairperson of the Board. Mr. Wold-Olsen is currently the chairman of the boards of directors of GN Store Nord A/S and Oncopeptides AB, and chair of the advisory committee of Novo Holdings, where he previously served as a member of its board of directors. Mr. Wold-Olsen also previously served as chairman of the boards of directors of Lundbeck A/S and the Medicines for Malaria Ventures, and as a member of the board of directors of Gilead Sciences, Inc. (NASDAQ: GILD). Mr. Wold-Olsen's experience includes a 30-year tenure at Merck & Co., Inc., where he served as President of the Human Health Intercontinental Division from 2005 to 2006, and prior to that, as President of Human Health Europe, Middle East/Africa and Worldwide Human Health Marketing from 1997 to 2005. Mr. Wold-Olsen is a former chair of the Europe Committee of the Pharmaceutical Research and Manufacturers of America, and previously served as a member of the board of directors of the European Federation of Pharmaceutical Industries and Associations. Mr. Wold-Olsen has dual MBAs in Management/Marketing from the University of Wisconsin and in Economics/Administration from the Norwegian School of Management. The Board believes Mr. Wold-Olsen has the appropriate skills to serve as a member of our Board based on his significant leadership and international business experience in the pharmaceutical industry.

**Vote Required** 

Proposals No. 1 will be approved if (i) on a show of hands, a majority of shareholders present in person or by proxy and voting on the proposal vote in favor of removing such director or (ii) on a poll, a majority of the shares present at the meeting in person or by proxy and voting on the proposal are voted in favor of removing such director. As a result, abstentions and broker non-votes will have no effect on the vote outcome. Abstentions and broker non-votes will be counted for the purpose of determining the presence of absence of a quorum, but will not be counted for the purpose of determining the number of votes cast on a given proposal.

Holders of proxies solicited by this Proxy Statement will vote the proxies received by them as directed on the WHITE proxy card or, if no direction is made, then (i) in the case of a holder of Ordinary Shares, "AGAINST" all proposals set forth in this Proxy Statement or (ii) in the case of an ADS Holder, the Depositary will deem such ADS Holder (unless otherwise specified in the notice distributed to ADS Holders) to have instructed the Depositary to vote "FOR" the items set forth in such voting instructions.

**THE BOARD UNANIMOUSLY RECOMMENDS A VOTE, USING THE WHITE PROXY CARD, "AGAINST"** 

**PROPOSAL NO. 1.** 

------

##### [**Table of Contents**](#toc)
**PROPOSAL NO. 2** 

**THAT IN THE EVENT ANY DIRECTOR IS APPOINTED AFTER THE COMPANY'S RECEIPT OF THE GENERAL MEETING REQUISITION NOTICE DATED JANUARY 10, 2023, AND PRIOR TO THE GENERAL MEETING, EACH SUCH DIRECTOR BE REMOVED FROM OFFICE AS A DIRECTOR OF THE COMPANY WITH IMMEDIATE EFFECT** 

Sarissa has proposed that in the event any director is appointed after the Company's receipt of the Requisition Notice, and prior to the General Meeting, each such director be removed from office as a director of the Company with immediate effect.

The Board does not expect to appoint any new directors to the Board between the date of the Company's receipt of the Requisition Notice and prior to the General Meeting. As a result, the Board believes that Proposal No. 2 is irrelevant.

**Vote Required** 

Proposal No. 2 will be approved if (i) on a show of hands, a majority of shareholders present in person or by proxy and voting on the proposal vote in favor of removing such director or (ii) on a poll, a majority of the shares present at the meeting in person or by proxy and voting on the proposal are voted in favor of removing such director. As a result, abstentions and broker non-votes will have no effect on the vote outcome. Abstentions and broker non-votes will be counted for the purpose of determining the presence of absence of a quorum, but will not be counted for the purpose of determining the number of votes cast on a given proposal.

Holders of proxies solicited by this Proxy Statement will vote the proxies received by them as directed on the WHITE proxy card or, if no direction is made, then (i) in the case of a holder of Ordinary Shares, "AGAINST" all proposals set forth in this Proxy Statement or (ii) in the case of an ADS Holder, the Depositary will deem such ADS Holder (unless otherwise specified in the notice distributed to ADS Holders) to have instructed the Depositary to vote "FOR" the items set forth in such voting instructions.

**THE BOARD UNANIMOUSLY RECOMMENDS A VOTE, USING THE WHITE PROXY CARD, "AGAINST"** 

**PROPOSAL NO. 2.** 

------

##### [**Table of Contents**](#toc)
**PROPOSAL NO. 3** 

**THAT EACH OF PATRICE BONFIGLIO, PAUL COHEN, MARK DIPAOLO, KEITH L. HORN, ODYSSEAS KOSTAS, LOUIS STERLING III AND DIANE E. SULLIVAN, HAVING CONSENTED TO ACT, BE APPOINTED AS AN ADDITIONAL DIRECTOR OF THE COMPANY WITH IMMEDIATE EFFECT.** 

Sarissa has proposed that Patrice Bonfiglio, Paul Cohen, Mark DiPaolo, Keith L. Horn, Odysseas Kostas, Louis Sterling III and Diane E. Sullivan, having consented to act, be appointed as an additional director of the Company with immediate effect at the General Meeting in an attempt to appoint seven new directors to the Board.

The NCG Committee, which acts as the Company's nominating committee, reviews and recommends to the Board potential nominees for election to the Board. In reviewing potential nominees, the NCG Committee considers the qualifications of each potential nominee in light of the Board's existing and desired mix of experience and expertise. Specifically, as set forth in the charter of the NCG Committee, it considers whether the nominee satisfies the following minimum criteria: has experience at a strategic or policymaking level in a business, government, non-profit or academic organization of high standing; is highly accomplished in his or her field, with superior credentials and recognition; is well regarded in the community and has a long-term reputation for the highest ethical and moral standards; has sufficient time and availability to devote to the affairs of the Company, particularly in light of the number of boards on which the nominee may serve; has a demonstrated history of actively contributing at board meetings (to the extent that the nominee serves or has previously served on other boards). In addition to these minimum qualifications, the NCG Committee recommends that the Board select persons for nomination to help ensure that: a majority of the Board shall be independent in accordance with in the listing standards of the Nasdaq Global Select Market; each of the Company's Audit, Remuneration and NCG Committees shall be comprised entirely of independent directors; and at least one member of the Audit Committee shall qualify as an audit committee financial expert as defined by SEC rules. In addition, the NCG Committee may consider whether the nominee has direct experience in the pharmaceutical, biotechnology or healthcare industries or in the markets in which the Company operates and whether the nominee, if elected, would assist in achieving a mix of Board members that represents a diversity of background and experience. Although the NCG Committee may consider whether nominees assist in achieving a mix of Board members that represents a diversity of background and experience, which is not only limited to race, gender or national origin, we have no formal policy regarding board diversity.

Members of the NGC Committee interviewed Mr. Kostas, Mr. DiPaolo and Ms. Bonfiglio as noted in the section of this Proxy Statement entitled "Background of the Solicitation". After assessing each of these candidates, the Board determined not to appoint Mr. Kostas, Mr. DiPaolo and Ms. Bonfiglio to the Board. Prior to its requisition, Sarissa never suggested Mr. Cohen, Mr. Horn, Mr. Sterling or Ms. Sullivan as potential director candidates. The NGC Committee has reviewed publicly available information regarding these candidates.

The Company has refreshed approximately 70% of the Board over the last year. Additionally, the Board believes that a 15-person Board is too large for a company this size.

**After reviewing the qualifications of potential Board candidates, the NCG Committee presents its recommendations to the Board, which selects the final director nominees. Our Board unanimously recommends that you vote the WHITE proxy card "AGAINST" all of the resolutions to be proposed at the General Meeting. The NCG Committee has conducted an evaluation of the prospective directors and carefully reviewed and considered each of the Sarissa Nominees. As of the date of this Proxy Statement, the Board has determined to recommend against Sarissa's proposal to add the seven Sarissa nominees to the Board. Our Board urges you not to sign or return any proxy card sent to you by Sarissa.** 

Exhibit A sets forth information relating to our directors and certain of our officers and employees who are considered "participants" in our solicitation under the SEC rules by reason of their position as directors of the Company or because they were soliciting proxies on our behalf.

------

##### [**Table of Contents**](#toc)
**If you have any questions or need assistance voting your shares, please contact the Company's proxy solicitors, Morrow Sodali LLC and Okapi Partners LLC, at:** 

---

| | |
|:---|:---|
| <br> Morrow Sodali LLC<br> 509 Madison Avenue, 12th Floor<br> New York, NY 10022<br> Toll-free: 1 (800) 662-5200<br> Collect: 1 (203) 658-9400<br> Email: AMRN@info.morrowsodali.com | ![LOGO](g424531g31y03.jpg) <br>1212 Avenue of the Americas, 17th Floor<br> New York, NY 10036<br> Telephone for Banks, Brokers, and International<br> Shareholders: +1 212-297-0720<br> Shareholders may call toll-free (from the U.S. and<br> Canada): 844-343-2625<br> Email: info@okapipartners.com |

---

**Vote Required** 

Under Section 160 of the Companies Act, at a general meeting of a public company, a motion for the appointment of two or more persons as directors of the Company by a single resolution must not be made unless a resolution that it should be so made has first been agreed to by the General Meeting without any vote being given against it (an "***Authorizing Resolution***"). The Company believes that an Authorizing Resolution is necessary for Proposal No. 3 to be validly presented and that if such an Authorizing Resolution is not passed, the Sarissa Nominees put forward in Proposal No. 3 cannot be validly elected. As a result, at the General Meeting, the Company expects that Sarissa will introduce an Authorizing Resolution to approve the use of the Proposal No. 3 to elect the Sarissa Nominees to the Board prior to consideration of Proposal No. 3. If Sarissa does not introduce such a resolution, the Company will plan to do so.

Assuming the Authorizing Resolution is approved, Proposal No. 3 will be approved and the Sarissa Nominees will be elected to the Board if (i) on a show of hands, a majority of shareholders present in person or by proxy and voting on the proposal vote in favor of Proposal No. 3 or (ii) on a poll, a majority of the Shares present at the meeting in person or by proxy and voting on the proposal are voted in favor of Proposal No. 3. As a result, abstentions and broker non-votes will have no effect on the vote outcome. Abstentions and broker non-votes will be counted for the purpose of determining the presence of absence of a quorum, but will not be counted for the purpose of determining the number of votes cast on a given proposal.

Holders of proxies solicited by this Proxy Statement will vote the proxies received by them as directed on the WHITE proxy card or, if no direction is made, then (i) in the case of a holder of Ordinary Shares, AGAINST all proposals set forth in this Proxy Statement or (ii) in the case of an ADS Holder, the Depositary will deem such ADS Holder (unless otherwise specified in the notice distributed to ADS Holders) to have instructed the Depositary to vote "FOR" the items set forth in such voting instructions.

**THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE** 

**"AGAINST"** 

**PROPOSAL NO. 3.** 

------

##### [**Table of Contents**](#toc)
**ADDITIONAL BUSINESS** 

As of the date of this Proxy Statement, we know of no other matters to be submitted to a vote of shareholders at the General Meeting. If any other matter is properly brought before the General Meeting or any adjournment thereof, it is the intention of the persons named in the enclosed proxy to vote the shares they represent in accordance with their judgment.

**SOLICITATION OF PROXIES** 

The Company will pay all of the costs of soliciting proxies on behalf of the Board. We will provide copies of our proxy materials to Citibank, N.A. as the Depositary, brokerage firms, fiduciaries and custodians for forwarding to beneficial owners and will reimburse these persons for their costs of forwarding these materials. Our directors and employees may also solicit proxies in person, by telephone or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the cost of forwarding Proxy Materials to beneficial owners.

We have engaged Morrow Sodali LLC and Okapi Partners LLC to assist us in the distribution and solicitation of proxies for a fee of $[●] plus expenses and $[●] plus expenses, respectively. Morrow Sodali LLC expects that approximately [●] of its employees will assist in the solicitation of proxies, and Okapi Partners LLC expects that approximately [●] of its employees will assist in the solicitation of proxies. The Company estimates that its additional out-of-pocket expenses will be $[●] in the aggregate, of which approximately $[●] has been spent to date. Such additional solicitation costs are expected to include the fees incurred to retain Morrow Sodali LLC and Okapi Partners LLC as the Company's proxy solicitors, as discussed above, fees of public relation advisors to advise the Company in connection with contested solicitation of proxies, increased mailing costs, such as the costs of additional mailings of solicitation materials to shareholders including printing costs, mailing costs and the reimbursement of reasonable expenses of banks, brokerage houses and other agents incurred in forwarding solicitation materials to beneficial owner and the costs of retaining an independent inspector of elections. Our directors, officers and employees may also solicit proxies; however, we will not pay them additional compensation for any of these services. Proxies may be solicited by email, telephone, facsimile or personal solicitation.

**YOUR VOTE IS IMPORTANT. A SHAREHOLDER OR ADS HOLDER MUST ACTIVELY VOTE TO HAVE AN IMPACT ON THE OUTCOME, POSITIVE OR NEGATIVE. WE STRONGLY ENCOURAGE SHAREHOLDERS AND ADS HOLDERS TO VOTE AND VOTE AGAINST ALL RESOLUTIONS IN ADVANCE OF THE GENERAL MEETING BY COMPLETING, DATING, SIGNING AND RETURNING A WHITE PROXY OR VOTING INSTRUCTION FORM AS PROMPTLY AS POSSIBLE IN ORDER TO ENSURE YOUR REPRESENTATION AT THE GENERAL MEETING. NOT VOTING OR ABSTAINING FROM VOTING WILL NOT HELP DEFEAT THESE HARMFUL RESOLUTIONS. IF YOU HAVE ANY QUESTIONS OR NEED ASSISTANCE VOTING YOUR SHARES, PLEASE CONTACT THE COMPANY'S PROXY SOLICITORS, MORROW SODALI LLC AND OKAPI PARTNERS LLC, AT:** 

---

| | |
|:---|:---|
| Morrow Sodali LLC<br> 509 Madison Avenue, 12th Floor<br> New York, NY 10022<br> Toll-free: 1 (800) 662-5200<br> Collect: 1 (203) 658-9400<br> Email: AMRN@info.morrowsodali.com | ![LOGO](g424531g31y03.jpg) <br>1212 Avenue of the Americas, 17th Floor<br> New York, NY 10036<br> Telephone for Banks, Brokers, and International<br> Shareholders: +1 212-297-0720<br> Shareholders may call toll-free (from the U.S. and<br> Canada): 844-343-2625<br> Email: info@okapipartners.com |

---

------

##### [**Table of Contents**](#toc)
**SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT** 

Based on information available to us and filings with the SEC, the following table sets forth certain information regarding the beneficial ownership (as defined by Rule 13d-3 of the Exchange Act) of our outstanding Ordinary Shares for (i) each of our directors, (ii) each of our "named executive officers," (iii) all of our directors and executive officers as a group, and (iv) persons known to us to beneficially hold more than 5% of our outstanding Ordinary Shares. Unless otherwise noted, the following information is presented as of January 11, 2023.

Beneficial ownership and percentage ownership are determined in accordance with the rules of the SEC and include voting or investment power with respect to our Ordinary Shares. This information does not necessarily indicate beneficial ownership for any other purpose. Under these rules, Ordinary Shares or ADSs, as the case may be, issuable under stock options, warrants, restricted stock units ("***RSUs***") or other convertible securities that are vested or exercisable within 60 days of January 11, 2023 are deemed outstanding for the purpose of computing the percentage ownership of the person holding the options or warrant(s) or other convertible securities but are not deemed outstanding for the purpose of computing the percentage ownership of any other person.

Unless otherwise indicated and subject to applicable community property laws, to our knowledge, each shareholder named in the following table possesses sole voting and investment power over their Ordinary Shares, except for those jointly owned with that person's spouse. Unless otherwise indicated below, the address of each person listed on the table is c/o Amarin Pharma, Inc., 440 US Highway 22, Bridgewater, New Jersey 08807.

The percentage of Shares beneficially owned is computed on the basis of 404,127,869 Ordinary Shares outstanding as of January 11, 2023.

---

| | | |
|:---|:---|:---|
| **Name and Address of Beneficial Owner** | **Shares Beneficially Owned** | **Shares Beneficially Owned** |
| **Name and Address of Beneficial Owner** | **Number** | **Percent of<br>Class** |
|  Greater than 5% Holders: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sarissa Capital Management LP(1) | 25210000 | 6.24 |
|  Current directors and named executive officers: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Karim Mikhail(2) | 766106 | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adam M. Berger |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Erin Enright |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jan van Heek(3) | 226705 | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Geraldine Murphy |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Per Wold-Olsen(4) | 252569 | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kristine Peterson(5) | 256384 | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Murray W. Stewart, D.M., F.R.C.P. |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alfonso Zulueta |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Steven B. Ketchum, Ph.D.(6) | 947574 | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aaron D. Berg(7) | 1099561 | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thomas C. Reilly |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Michael W. Kalb(8) | 736596 | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jason Marks(9) | 255873 | \* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All current directors and executive officers as a group (12 persons)(10) | 3548899 | \* |

---

------

\* Represents beneficial ownership of less than one percent. 

(1) Based on information provided in a Schedule 13D/A filed by Sarissa Capital, Alexander J. Denner (together with
Sarissa Capital, the "  ***Sarissa Reporting Persons***") and Louis Sterling III on January 11, 2023. Sarissa Capital and the fund and other private investment vehicles for which Sarissa Capital acts as the investment advisor
own the 25,210,000 Shares (the "  ***Sarissa Shares*** "). Sarissa Capital has the authority to vote and to

------

##### [**Table of Contents**](#toc)
dispose of the Sarissa Shares. Alexander J. Denner, Ph.D is the Chief Investment Officer, and by virtue of his control of the ultimate general partner, of Sarissa Capital, and, by virtue of such positions, may be deemed to have beneficial ownership of the Shares. The address for Sarissa Capital and Alexander J. Denner is 660 Steamboat Road, Greenwich, CT 06830. Mr. Sterling may be deemed to be the beneficial owner of an additional 117,772 Shares (the "***Sterling Shares***"). Mr. Sterling has sole power to vote and dispose the Sterling Shares. The address for Mr. Sterling is 133 Gale Drive, Beverly Hills, CA 90211. The Sarissa Reporting Persons and Mr. Sterling may be deemed to have formed a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended, and may be deemed to beneficially own, in the aggregate, 25,327,772 Shares representing approximately 6.26% of the outstanding Shares. The Sarissa Reporting Persons disclaim beneficial ownership of the Sterling Shares. Mr. Sterling disclaims beneficial ownership of the Sarissa Shares.

(2) Includes 114,784 Shares directly owned, 410,288 Shares issuable upon the exercise of options exercisable within
60 days of January 11, 2023, and 241,034 Shares issuable upon the vesting of RSUs within 60 days of January 11, 2023.

(3) Includes 14,168 Shares directly owned and 212,537 Shares issuable upon the exercise of options exercisable
within 60 days of January 11, 2023.

(4) Includes 149,000 Shares directly owned and 103,569 Shares issuable upon the exercise of options exercisable
within 60 days of January 11, 2023.

(5) Includes 256,384 Shares issuable upon the exercise of options exercisable within 60 days of January 11,
2023. (6) Includes 544,021 Shares directly owned, 323,519 Shares issuable upon the exercise of options exercisable within
60 days of January 11, 2023, and 80,034 Shares issuable upon the vesting of RSUs within 60 days of January 11, 2023.

(7) Includes 451,180 Shares directly owned, 539,214 Shares issuable upon the exercise of options exercisable within
60 days of January 11, 2023, and 109,167 Shares issuable upon the vesting of RSUs within 60 days of January 11, 2023.

(8) Includes 337,314 Shares directly owned per his final Form 4 filed on August 2, 2022 and 399,282 Shares
issuable upon the exercise of options exercisable within 60 days of January 11, 2023.

(9) Includes 21,917 Shares directly owned per his final Form 4 filed on August 23, 2022, 99,388 Shares
issuable upon the exercise of options exercisable within 60 days of January 11, 2023, and 134,568 Shares issuable upon the vesting of RSUs within 60 days of January 11, 2023.

(10) Includes an aggregate of 1,273,153 Shares directly owned, 1,845,511 Shares issuable upon the exercise of
options exercisable within 60 days of January 11, 2023 and 430,235 Shares issuable upon the vesting of RSUs within 60 days of January 11, 2023 held by our current directors and executive officers as a group.

------

##### [**Table of Contents**](#toc)
**PRELIMINARY – SUBJECT TO COMPLETION** 

**PROXY FORM** 

**AMARIN CORPORATION PLC** 

**THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS** 

**For use at the General Meeting to be held at [**●**] at [**●**] [a.m./p.m.] on [**●**], 2023.** 

I/We<u> </u>

(Name in full block capitals please)

of<u> </u>

being (a) member(s) of Amarin Corporation plc (the **"Company"**) hereby appoint the Chairman of the meeting or (*see note 6 below*)

------

as my/our proxy to attend, speak and vote for me/us and on my/our behalf as identified by an "X" in the appropriate box below at the General Meeting of the Company to be held at [●] [a.m./p.m.] on [●], 2023 and at any adjournment of the General Meeting. The proxies, in their discretion, are further authorized to vote against the election of a person to the Board of Directors of the Company if any nominee named becomes unable to serve for good cause will not serve.

This form of proxy relates to the resolutions referred to below.

I/We instruct my/our proxy to vote as follows:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Resolutions Proposed by (i) Sarissa Capital Catapult Fund LLC, (ii) Sarissa Capital Hawkeye Fund LP, (iii) ISP Fund LP, (iv) Sarissa Capital Offshore Master Fund LP, (v) Sarissa Capital Master Fund II LP and (vi) Sarissa Capital Athena Fund Ltd.** | **For** | **Against** | **Abstain**<br> *(see note 2)* | **Discretionary**<br> *(see note 3)* |
| &nbsp;&nbsp;&nbsp;1. | That Per Wold-Olsen be removed from office as a director of the Company with immediate effect. |  |  |  |  |
| &nbsp;&nbsp;&nbsp;2. | That in the event any director is appointed after the Company's receipt of the general meeting requisition notice dated January 10, 2023, requiring the Company to convene the General Meeting, and prior to the General Meeting, each such director be removed from office as a director of the Company with immediate effect. |  |  |  |  |
| &nbsp;&nbsp;&nbsp;3. | That each of Patrice Bonfiglio, Paul Cohen, Mark DiPaolo, Keith L. Horn, Odysseas Kostas, Louis Sterling III and Diane E. Sullivan, having consented to act, be appointed as an additional director of the Company with immediate effect. |  |  |  |  |

---

Dated     <br> Signature(s)    

**This proxy, when properly executed, will be voted in the manner directed therein. If no such direction is made, this proxy will be voted in accordance with the Board of Director's recommendations.** 

------

##### [**Table of Contents**](#toc)
Notes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Please indicate with an "X" in the appropriate box how you wish the proxy to vote. In the absence of
any indication, the proxy will be voted in accordance with the recommendations of the Board of Directors. The proxy may also vote or abstain from voting as he/she thinks fit on any other business which may properly come before the meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. If you mark the box "abstain", it will mean that your proxy will abstain from voting and,
accordingly, your vote will not be counted either for or against the relevant resolution.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. If you mark the box "discretionary", the proxy can vote as it chooses or can decide not to vote at
all.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. The form of proxy should be signed and dated by the member or his attorney duly authorised in writing. If the
appointer is a corporation this proxy should be under seal or under the hand of an officer or attorney duly authorised. Any alteration made to the form of proxy should be initialed.

5. To be valid, this form of proxy, together with a duly signed and dated power of attorney or any other authority (if any) under which it is executed (or a notarially certified copy of such power of attorney or other authority) must be signed and dated and lodged at the Company's registrars at the address below, so as to be received by [●] [a.m./p.m.] on [●], 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. A proxy need not be the Chairman of the meeting. A member may appoint a proxy of his/her own choice. If you
wish to appoint someone else to act as your proxy, you may strike out the words "the Chairman of the meeting" and insert the name of the person whom you wish to appoint to act as your proxy in the space provided. All amendments to this
form must be initialed. If you sign and return this form with no name inserted in the space provided, the Chairman of the meeting will be deemed to be your proxy. A member may appoint more than one proxy in relation to the meeting provided that each
proxy is appointed to exercise rights attached to different shares. A proxy need not be a member of the Company but must attend the meeting. Where someone other than the Chairman of the meeting is appointed as a proxy, the member appointing him/her
is responsible for ensuring that they attend the meeting and are aware of his/her voting intentions. If a member wishes his/her proxy to speak on his/her behalf at the meeting, he/she will need to appoint someone other than the Chairman of the
meeting and give his/her instructions directly to them.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. In the case of joint holders, signature of any one holder will be sufficient, but the names of all the joint
holders should be stated. The vote of the senior holder (according to the order in which the names stand in the register of members in respect of the holding) who tenders a vote in person or by proxy will be accepted to the exclusion of the vote(s)
of the other joint holder(s).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. Completion and return of a form of proxy will not preclude a member from attending, speaking and voting at the
meeting or any adjournment thereof in person. If a proxy is appointed and the member attends the meeting in person, the proxy appointment will automatically be terminated.

<u>Address for lodgment of Proxies</u>:

Equiniti

Aspect House

Spencer Road

Lancing

West Sussex

United Kingdom

BN99 6DA

------

##### [**Table of Contents**](#toc)
**<u>EXHIBIT A</u>**

**SUPPLEMENTAL INFORMATION REGARDING PARTICIPANTS** 

Amarin Corporation plc ("***Amarin***" or the "***Company***") is referred to in this Exhibit A as "we," "us" and "our."

The following tables ("Directors" and "Officers and Employees") set forth the name, present principal occupation and business address of each of the Company's directors, officers and employees who, under the rules of the Securities and Exchange Commission (the "***SEC***"), are considered to be "participants" in our solicitation of proxies from our shareholders in connection with the General Meeting.

**<u>Directors</u>**

The name and present principal occupation of each of our directors are set forth below. The business address of our current directors is c/o Amarin Pharma, Inc., 440 US Highway 22, Bridgewater, New Jersey 08807.

---

| | |
|:---|:---|
| **Name** | **Principal Occupation** |
|  Erin Enright | Managing Member, Prettybrook Partners LLC |
|  Jan van Heek | Principal, Partner, BioPoint Group LLC |
|  Karim Mikhail | President, Chief Executive Officer, Amarin Corporation plc |
|  Per Wold-Olsen | Chairman of Board of Directors, Lundbeck A.S and GN Store Nord A/S |
|  Kristine Peterson | Former (Retired) Chief Executive Officer, Valeritas, Inc. |
|  Alfonso Zulueta | Former (Retired) President, International Business Unit, Eli Lilly and Company |
|  Geraldine Murphy | Founder and Managing Partner, Evolution-Partners |
|  Adam M. Berger | Managing Partner, Three Peaks Partners |
|  Murray W. Stewart, D.M., F.R.P.C. | Chief Medical Officer, Rhythm Pharmaceuticals, Inc. |

---

**<u>Officers and Employees</u>**

The names and principal occupation of our executive officers and employees who are considered "participants" in our solicitation of proxies are set forth below. The principal occupation refers to such person's position with the Company, and the business address for each person is Amarin Pharma, Inc., 440 US Highway 22, Bridgewater, New Jersey 08807.

---

| | |
|:---|:---|
| **Name** | **Principal Occupation** |
|  Karim Mikhail | President, Chief Executive Officer and Director |
|  Thomas C. Reilly | Chief Financial Officer |
|  Lisa DeFrancesco | Senior Vice President, Corporate Affairs and Investor Relations |

---

**<u>Information Regarding Ownership of Amarin Securities by Participants</u>**

The number of our Ordinary Shares held by our directors and named officers as of January 11, 2023 is set forth under the "Security Ownership of Certain Beneficial Owners and Management" section of the proxy statement for the General Meeting.

The number of shares of Ordinary Shares held by our other employees and officers who are considered "participants" in our solicitation of proxies are set forth in the below table, including the number of securities

------

##### [**Table of Contents**](#toc)
beneficially owned by such employees and officers as of January 11, 2023 for which beneficial ownership can be acquired within 60 days of such date.

---

| | | |
|:---|:---|:---|
|  | **BENEFICIAL OWNERSHIP(1)** | **BENEFICIAL OWNERSHIP(1)** |
| **BENEFICIAL OWNER** | **NUMBER OF**<br>**SHARES** | **PERCENT OF**<br>**TOTAL** |
|  Lisa DeFrancesco | 75001 | \* |
|  All current executive officers and directors as a group (12 persons) | 3548899 | \* |

---

\* Less than 1% of the outstanding shares of our common stock. 

---

| | |
|:---|:---|
| 1 | Beneficial ownership and percentage ownership are determined in accordance with the rules of the SEC and include voting or investment power with respect to our Ordinary Shares. This information does not necessarily indicate beneficial ownership for any other purpose. Under these rules, Ordinary Shares, or ADSs, as the case may be, issuable under options, warrants, RSUs or other convertible securities that are vested or exercisable within 60 days of January 11, 2023 are deemed outstanding for the purpose of computing the percentage ownership of the person holding the options, RSUs, warrant(s) or other convertible securities but are not deemed outstanding for the purpose of computing the percentage ownership of any other person. On January 11, 2023, we had 404,127,869 Ordinary Shares outstanding. Unless otherwise indicated, the address of all listed shareholders is c/o Amarin Pharma, Inc., 440 US Highway 22, Bridgewater, New Jersey 08807. Each of the shareholders listed has sole voting and investment power with respect to the shares beneficially owned by the shareholder unless noted otherwise, subject to community property laws where applicable.  |

---

**<u>Ordinary Shares Purchased or Sold</u>**

The following table sets forth information regarding purchases and sales of the Company's securities by each participant during the past two years. No part of the purchase price or market value of these securities is represented by funds borrowed or otherwise obtained for the purpose of acquiring or holding such securities.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Transaction<br>Date** | **# of<br>Shares** | **Description** | **Description** | **Security** |
| Adam M. Berger | 10/20/2022 | 302122 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | Warrants/Options |
|  | 10/20/2022 | 247707 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Transaction<br>Date** | **# of<br>Shares** | **Description** | **Description** | **Security** |
| Lisa DeFrancesco | 02/01/2022 | 100000 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | Warrants/Options |
|  | 02/01/2022 | 100000 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Transaction<br>Date** | **# of<br>Shares** | **Description** | **Description** | **Security** |
| Erin Enright | 06/27/2022 | 115919 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | Warrants/Options |
|  | 06/27/2022 | 93750 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |
|  | 05/16/2022 | 223719 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | Warrants/Options |
|  | 05/16/2022 | 180000 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |

---

------

##### [**Table of Contents**](#toc)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Transaction<br>Date** | **# of<br>Shares** | **Description** | **Description** | **Security** |
| Karim Mikhail | 12/30/2022 | 11367 | Disposition | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | RSUs (Restricted Stock Units) |
|  | 12/30/2022 | 11367 | Acquisition | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Ordinary Shares |
|  | 12/30/2022 | 1270 | Disposition | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Ordinary Shares |
|  | 07/01/2022 | 33333 | Disposition | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | RSUs (Restricted Stock Units) |
|  | 07/01/2022 | 33333 | Acquisition | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Ordinary Shares |
|  | 07/01/2022 | 10780 | Disposition | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Ordinary Shares |
|  | 04/12/2022 | 71734 | Disposition | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | RSUs (Restricted Stock Units) |
|  | 04/12/2022 | 71734 | Acquisition | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Ordinary Shares |
|  | 04/12/2022 | 20631 | Disposition | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Ordinary Shares |
|  | 02/04/2022 | 791300 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | Warrants/Options |
|  | 02/04/2022 | 623100 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |
|  | 12/31/2021 | 11367 | Disposition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |
|  | 12/31/2021 | 11367 | Acquisition | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Ordinary Shares |
|  | 12/31/2021 | 3876 | Disposition | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Ordinary Shares |
|  | 07/01/2021 | 33334 | Disposition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |

---

------

##### [**Table of Contents**](#toc)

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Transaction<br>Date** | **# of<br>Shares** | **Description** | **Description** | **Security** |
| 07/01/2021 | 33334 | Acquisition | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Ordinary Shares |
| 07/01/2021 | 9794 | Disposition | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Ordinary Shares |
| 04/12/2021 | 290200 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | Warrants/Options |
| 04/12/2021 | 215200 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |
| 01/04/2021 | 46000 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | Warrants/Options |
| 01/04/2021 | 34100 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Transaction<br>Date** | **# of<br>Shares** | **Description** | **Description** | **Security** |
| Geraldine Murphy | 10/20/2022 | 302122 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | Warrants/Options |
|  | 10/20/2022 | 247707 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Transaction<br>Date** | **# of<br>Shares** | **Description** | **Description** | **Security** |
| Kristine Peterson | 06/27/2022 | 115919 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | Warrants/Options |
|  | 06/27/2022 | 93750 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |
|  | 06/14/2021 | 45953 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | Warrants/Options |
|  | 06/14/2021 | 36000 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Transaction<br>Date** | **# of<br>Shares** | **Description** | **Description** | **Security** |
| Thomas C. Reilly | 07/01/2022 | 100000 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | Warrants/Options |
|  | 07/01/2022 | 100000 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Transaction<br>Date** | **# of<br>Shares** | **Description** | **Description** | **Security** |
| Murray W. Stewart, D.M., F.R.P.C. | 1/9/2023 | 223560 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | Warrants/Options |
|  | 1/9/2023 | 182433 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |

---

------

##### [**Table of Contents**](#toc)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Transaction<br>Date** | **# of<br>Shares** | **Description** | **Description** | **Security** |
| Jan Van Heek | 06/27/2022 | 115919 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | Warrants/Options |
|  | 06/27/2022 | 93750 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |
|  | 06/14/2021 | 45953 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | Warrants/Options |
|  | 06/14/2021 | 36000 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Transaction<br>Date** | **# of<br>Shares** | **Description** | **Description** | **Security** |
| Per Wold-Olsen | 06/27/2022 | 122359 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | Warrants/Options |
|  | 06/27/2022 | 98959 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |
|  | 06/13/2022 | 55000 | Acquisition | Open market or private purchase of non-derivative or derivative security | Ordinary Shares |
|  | 01/10/2022 | 103569 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | Warrants/Options |
|  | 01/10/2022 | 81082 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Name** | **Transaction<br>Date** | **# of<br>Shares** | **Description** | **Description** | **Security** |
| Alfonso Zulueta | 06/27/2022 | 115919 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | Warrants/Options |
|  | 06/27/2022 | 93750 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |
|  | 05/16/2022 | 223719 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | Warrants/Options |
|  | 05/16/2022 | 180000 | Acquisition | Grant, award, or other acquisition pursuant to Rule 16b-3(d) | RSUs (Restricted Stock Units) |

---

**<u>Miscellaneous Information Concerning Participants</u>**

Other than as set forth in this Exhibit A or the Proxy Statement, none of the participants or their associates

(i) beneficially owns, directly or indirectly, any Ordinary Shares of the Company or any of its subsidiaries or (ii) has any substantial interest, direct or indirect, by security holdings or otherwise, in any matter to be acted upon at the General Meeting. In addition, neither we nor any of the participants listed above has been within the past year a party to any contract, arrangement or understanding with any person with respect to any of our securities, including, but not limited to, joint ventures, loan or option arrangements, puts or calls, guarantees against loss or guarantees of profit, division of losses or profits or the giving or withholding of proxies.

Other than as set forth in this Exhibit A or the Proxy Statement, neither we nor any of the participants listed above or any of their associates have or will have (i) any arrangements or understandings with any person with respect to any future employment by us or our affiliates or with respect to any future transactions to which we or any of our affiliates will or may be a party or (ii) a direct or indirect material interest in any transaction or series of similar transactions since the beginning of our last fiscal year or any currently proposed transactions, or series of similar transactions, to which we or any of our subsidiaries was or is to be a party in which the amount involved exceeds $120,000.

None of the participants listed has been convicted in a criminal proceeding within the past ten (10) years.